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Abstract 14 
An experimental/computational approach has been successfully applied in order to study the 15 
effect of solubilizing vehicles (cyclodextrins and liposomes) on the passive diffusion of four 16 
active pharmaceutical ingredients (API) of different nature (hydrophilic, ionizable and 17 
lipophilic) through an unstirred water layer (UWL) model. This approach allowed the 18 
measurement of flux changes through the UWL and the computational calculation of different 19 
parameters relevant to interpret the interplay within solubilizing vehicles and UWL diffusion. 20 
In the case of cyclodextrin, this approach allowed the determination of free drug diffusivity 21 
(Df), bound drug diffusivity (Db) and the equilibrium constant (K). In the case of liposomes, 22 
the experimental approach allowed the determination of the liposomes/water partition 23 
coefficient (Plip/w) as well as relative API diffusivity ((𝐷), i.e. the drug diffusion in the 24 
presence of solubilizing agents). This work demonstrates that the presence of solubilizing 25 
vehicles hampers the diffusion of API through UWL due to a combination of reduction in 26 
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relative diffusivity and concentration gradient. These results are highly relevant as they might 27 
help to explain why biological performance of API is affected by the presence of 28 
solubilizing/complexing agents. 29 
Keywords: Unstirred water layer, passive diffusion, gradient of concentration, solubilizing 30 
agents, cyclodextrin, liposomes. 31 
 32 






1. Introduction 37 
More than 40% of marketed drugs and 90% of new chemical entities under development with 38 
promising pharmaceutical activities suffer from poor water solubility [1]. In an attempt to 39 
increase the biopharmaceutical performance of these compounds one approach that has been 40 
extensively studied in the recent year has been the employment of solubilizing agents [2] 41 
under the assumption that increased apparent aqueous solubility of the drug will result in 42 
increased bioavailability. Since their first descriptions in the middle of last century 43 
cyclodextrins and liposomes have been heavily studied in light of their strong ability to 44 
solubilize lipophilic compounds [3, 4]. Cyclodextrins are capable of solubilizing lipophilic 45 
entities due to inclusion complexes formation [5] whereas liposomes incorporate lipophilic as 46 
well as amphiphilic moieties in the phospholipid bilayers of which liposomes consist of [4]. 47 
Even though in most cases these entities are capable of solubilizing poorly soluble substances 48 
of orders of magnitude [6, 7] resulting in a positive enhancement of bioavailability, in some 49 
cases biopharmaceutical performances are reduced [8].  It has been suggested that the 50 
negative influence of some solubilizing agents (dose dependent effect [9]) on 51 
biopharmaceutical performance of drug is related to a reduction in API transport (i.e. mass 52 
transfer) through biological barriers.  Furthermore, some studies have emphasized the role of 53 
the unstirred water layer (UWL [10, 11]) as the limiting step of the transport process through 54 
barriers [12, 13]. The UWL represents an additive aqueous layer that covers biological 55 
barriers where conditions of stagnation hold [14] and that drug molecules need to cross before 56 
entering in contact with the lipophilic environment represented by cell membranes [12, 13]. 57 
Considering the UWL as a homogeneous environment, where molecules will spontaneously 58 
diffuse through, the flux (j) of an API through this layer can be described by Fick’s first low 59 








In this equation, D represents the diffusion coefficient of API molecules in the UWL and 61 
dc/dx the local concentration gradient. Brewster et al. [15] investigated the effective 62 
permeability of different drugs and hydroxypropyl-β-cyclodextrin (HPBCD) through a 63 
parallel artificial membrane permeability assay (PAMPA) in the presence of UWL of 64 
different thickness. They found that, for molecules with high affinity for HPBCD (i.e. 65 
lipophilic) the permeability of the drug was reduced by increased cyclodextrin concentration, 66 
whereas, for compound with low HPBCD-API equilibrium constant (K), no significant 67 
reduction was observed. Dahan et al. [16, 17] tried to describe the interplay between 68 
permeability/complexing agents and UWL with the quasi-equilibrium mathematical model. In 69 
this case they utilized a cellular-based permeability assay (Caco-2), PAMPA and an animal 70 
model in order to investigate the effective permeability of drugs in the presence and absence 71 
of cyclodextrins in order to understand the role of UWL in drug permeability in presence of 72 
complexing agents. In accordance with Brewster at al. they have found a correlation between 73 
reduction in drug permeability and HPBCD concentration.  Some mechanistic explanations 74 
have been suggested to describe this interesting phenomenon [15-17]. One hypothesis is that 75 
HPBCD reduces the amount of free fraction of drug available, decreasing the concentration 76 
gradient (dc/dx) and therefore reducing the net flux of drug molecules through the UWL (Eq. 77 
1) [17]. Another explanation that has been proposed is related to partitioning and 78 
permeability. According to Fine-Shamir et al. [18] the presence of cyclodextrin should reduce 79 
the ability of API molecules to distribute through the lipophilic environment (i.e. reduction in 80 
apparent distribution coefficient) negatively affecting the net transport of the drug through the 81 
whole barrier. Stewart et al. (2017) introduced a new analytical method capable of 82 
discriminating the limiting step in permeability within UWL or the membrane in the presence 83 
of bioavailability-enhancing drug products [19]. They identify two main mechanisms of 84 
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permeation, in which the API flux through the barrier is influenced by the total concentration 85 
gradient of the drug (i.e. free drug and bound drug) only when the UWL is the limiting step of 86 
the permeation. Even though all these studies indicate UWL as responsible for the reduction 87 
of the overall mass transfer in the presence of solubilizing agents, a proper mechanistic 88 
explanation of the phenomena is still missing. The aim of this work is to experimentally 89 
measure and mathematically describe the diffusion of API molecules through an UWL in the 90 
presence of two types of solubilizing vectors: cyclodextrins and liposomes. In this work we 91 
applied the analytical/computational approach based on temporal resolution of diffusion 92 
profiles in UWL recently introduced by us [20] in order to effectively quantify the changes in 93 
API flux through an UWL in the presence of solubilizing vectors. In this way we could derive 94 
all parameters relevant for the characterization of diffusion process namely, diffusivities, 95 
equilibrium constants and concentration gradients. This new approach is quite unique as it 96 
allows the real-time measurement of relative flux changes, allowing the direct 97 
characterization of all relevant parameters in the UWL. The results obtained in this work 98 
highlight the role that the UWL plays in permeation of drugs, especially when solubilizing 99 
vehicles are present. 100 
2. Materials and Methods 101 
2.1 Materials 102 
All buffering agents (sodium dihydrogen phosphate monohydrate (NaH2PO4·H2O), disodium 103 
hydrogen phosphate dodecahydrate (Na2HPO4·12H2O), sodium chloride (NaCl) and sodium 104 
hydroxide (NaOH)), active ingredients (caffeine(caf), ibuprofen (ibu), ibuprofen sodium salt 105 
(Na-ibu) ketoprofen (ket) and hydrocortisone (hc), Table 1) and organic solvent employed in 106 
this work (methanol) were purchased form Sigma Aldrich Chemie GmbH (Steinheim, 107 
Germany). Soy phosphatidylcholine (S-100) was a generous gift form Lipoid GmbH 108 
(Ludwigshafen, Germany). 2-hydroxylpropyl β-cyclodextrin (HPBCD) with estimated 109 
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molecular weight of 1396 g/mol and average degree of substitution within 0.5-1.3 (defined as 110 
unit of 2-hydroxypropyl per glucose unit) was also purchased form Sigma Aldrich or, 111 
alternatively, from Roquette Freres (Lestrem, France). 112 
Table 1: Molecular weight (mw), ionization constant (pKa) distribution coefficient at pH 7.4 113 
(LogD7.4), topological polar surface area (TPSA) and molar volume (Vm) of the investigated 114 
compounds. 115 
Drug mw pKa[21] LogD7.4 TPSA[21] Vm[24] 
 g/mol   Å2 cm3/mol 
caf 194.2 10.4 -0.03[22] 58.4 133 
hc 362.5 -  1.51[22] 98.4 281 
Ibu/Na-ibu 206.3/228.3 4.91/≈  1.00[23]/≈ 37.3/≈ 200/≈ 
Ket 254.2 4.45  0.19[23] 54.4 212 
 116 
2.2 UV-visible localized spectroscopy 117 
2.2.1 API solutions preparation 118 
In order to obtain a 73 mM neutral (pH 7.4) and isotonic (280-290 mOsm) phosphate buffer 119 
saline (PBS), a solution of NaH2PO4·H2O (2.2% W/V) was mixed in a ratio 1:5 with a 120 
solution of Na2HPO4·12H2O (1.8% W/V). The pH of was subsequently adjusted to 7.3−7.4 121 
(pH meter Lab 744, Metrohm AG, Herisau, Switzerland) by the addition of NaOH solid 122 
pellets whereas the tonicity was brought to 280−290 mOsm (Semi-Micro Osmometer K-7400, 123 
Knauer, Berlin, Germany) by the addition of NaCl solid crystals. Each of the API investigated 124 
was dissolved in the PBS solution in order to achieve a final drug concentration in the range 125 
1- 6 mM.  126 
2.2.2 Cyclodextrin-API samples preparation 127 
The complexation studies were conducted following the basic principle of standard phase-128 
solubility studies [25] therefore exposing the same amount of API to increasing concentration 129 
7 
 
of the complexing agent. For caffeine, hydrocortisone and ketoprofen, a stock solution of the 130 
complexing agent (in this work HPBCD) was prepared dissolving approximatively 3.6 g of 131 
cyclodextrin derivative in PBS in order to obtain a 50 mM HPBCD solution. One mL of drug 132 
solution was mixed together with increasing volumes of HPBCD stock solution (form 0 mL 133 
up to 1 mL)  inside standard Eppendorf vials, in order to achieve a minimum of 5 samples 134 
with increased cyclodextrin concentration (ranging from 0 mM up to 25 mM) and constant 135 
API concentration (samples caf0-4, hc0-4, ibu0-5, ket1-5 in Table 2).  136 
Table 2. Concentration of active pharmaceutical ingredient (API), 2-hyrdoxypropil β-137 
cyclodextrin (HPBCD), soy phosphatidylcholine (SPC) and buffer in each of the samples 138 
investigated. Each sample was analyzed at maximum wavelength of absorption (λmax) and the 139 







Buffer conc. λMAX ε 
 mM mM mM mM nm cm2/µmol 
Caffeine 
caf0 0.9 - - 72.8 272 9.7 
caf1 // 1 - // // // 
caf2 // 5 - // // // 
caf3 // 10 - // // // 
caf4 // 25 - // // // 
caf5 // - 25 // // // 
Hydrocortisone 
hc0 0.5 - - 72.8 247 11.9 
hc1 // 1 - // // // 
hc2 // 2.5 - // // // 
hc3 // 10 - // // // 
hc4 // 25 - // // // 
hc5 // - 25 // // // 
Ibuprofen 
ibu0 1.3 - - 72.8 221 9.0 
ibu1 // 0.5 - // // // 
ibu2 // 1 - // // // 
ibu3 // 2.5 - // // // 
ibu4 // 5 - // // // 
ibu5 // 10 - // // // 
ibu6 // - 25 // // // 
Ketoprofen 
ket0 1.4 - - 72.8 260 16.5 
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ket1 // 0.5 - // // // 
ket2 // 2.5 - // // // 
ket3 // 5 - // // // 
ket4 // 10 - // // // 
ket5 // 25 - // // // 
ket6 // - 25 // // // 
 141 
For ibu, 0.4 mL of API stock solution in PBS (6.32 mM) were mixed inside standard 2 mL 142 
Eppendorf vials with increasing volumes (form 0.0 mL to 1.0 mL) of a 20 mM HPBCD PBS 143 
solution (Table 2). PBS was used in order to fill in the missing volume up to two mL. 144 
Samples were stored at room temperature prior to analysis.  145 
2.2.3 Liposomes-API samples preparation  146 
A liposomal dispersion was prepared following the standard thin-film hydration method [26]. 147 
In brief, approximatively 2 g soy phosphatidylcholine (S-100) were dissolved into 50 mL of 148 
methanol in a round bottom flask. The organic solvent was removed by controlled vacuum 149 
evaporation (25°C; 1 hour; 60–65 mBar final vacuum) employing a Büchi rotary evaporator 150 
system (model R-124), equipped with a water bath (model B-480) and vacuum pump (model 151 
V-500; Büchi Labortechnik AG, Flawil, Switzerland). Large liposomes dispersion was 152 
obtained by reconstituting the lipid film obtained after solvent removal with 50 mL PBS. The 153 
liposomal dispersion was subsequently extruded throw 800 nm (4 cycles) and 400 nm (4 154 
cycles) polycarbonate filters (Whatman International Ltd., Bucking-hamshire, UK) in order to 155 
obtain a homogeneous dispersion of medium-sized liposomes (average diameter 156 
approximately 400 nm). Prior to analysis, one mL of the liposomal dispersion was mixed with 157 
1 mL of API solution inside an Eppendorf vial (samples caf5, hc5, ibu6 and ket6 in Table 2). 158 
Samples were incubated for 10 min prior to analysis.  159 
2.2.4 Analytical method 160 
The analytical method recently introduced by us [20] was employed in this work to 161 
investigate the influence of cyclodextrins and liposomes on API diffusion in aqueous media. 162 
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For the spectrophotometric measurements, a double array VWR (VWR International, Radnor, 163 
USA) UV-visible spectrophotometer (model UV-6300 PC) equipped with a Hellma® 164 
Suprasil® (Sigma-Aldrich) quartz absorption cuvettes (chamber volume of 700 µL and path 165 
length of 10 mm) was employed. Both reference and sample cuvette were filled with the same 166 
volume of distilled water (675 µl and placed in the respective compartment of the 167 
spectrophotometer). At time (t) = 0 sec (starting of the experiment), 25 µL of one sample were 168 
gently injected in the bottom of the sample cuvette by a needle syringe. In order to avoid 169 
evaporation of water, the sample cuvette was sealed with parafilm right after sample injection. 170 
Absorbance readings were recorded at fixed wavelength (corresponding to the λMAX of each 171 
of the compounds, Table 2) at regular time intervals (120 sec) for 18 hours at room 172 
temperature (23-24°C). Absorbance was recorded at 0.51 cm from the bottom of the cuvette 173 
(hm).  174 
2.2.5 Mathematical data treatment 175 
The mathematical approach previously described by us [20] was employed in order to 176 
calculate both reference diffusivity (D0, the diffusivity of the API in absence of solubilizing 177 
vehicles) and apparent diffusivities (𝐷, the diffusivity measured in the presence of 178 
solubilizing vectors). In brief, the spontaneous process of molecules migrating through a 179 








In this equation, c represents the concentration of the substance (in this case the API 181 
concentration), t the time, x the position, and D the diffusivity. 182 
Assuming times (t) and positions (x) such that t ≪ h2/D and x ≪ h (where h is 3.30 cm, the 183 











Where σ represents the width of the initial distribution (considered to be a half gaussian 185 
curve) and A represents the initial amount of the API. Equation 3 was fitted to the 186 
experimental data in order to find the best solutions for both D, A and σ.  187 
The calculation of constant of equilibrium (K) was based on the assumption that for the 1:1 188 
complex (L·S) formation between API molecules (i.e. the substrate, S) and a ligand (Eq. 4): 189 
𝐿 + 𝑆 ⇋ 𝐿 · 𝑆 Equation 4 
For an ideal diluted solution, it can be assumed that the equilibrium constant (K) of 190 






Knowing the initial concentration of the ligand (L0), the substrate (S0) and the equilibrium 192 
concentration of the complex (Q), equation 5 can be re arranged as: 193 
𝐾 =
𝑄
(𝑆 − 𝑄)(𝐿 − 𝑄)
 
Equation 6 
Solving this expression yields two values for Q, whereof only one lies in the range  194 




1 + (𝐿 + 𝑆 )𝐾 − 1 + 2(𝐿 + 𝑆 )𝐾 + (𝐿 − 𝑆 ) 𝐾   
Equation 7 
Assuming fast exchange between API in the free and the bound states, the measured value for 196 
diffusion (𝐷) will be the weighted average of the diffusions of the free and bound molecules 197 
(Db and Df  respectively). The relationship between the different diffusivities is described by 198 
Eq. 8:  199 
𝐷 = 𝑀𝐹 𝐷 + 𝑀𝐹 𝐷 =
𝑄
𝐿
𝐷 + 1 −
𝑄
𝐿
𝐷 = 𝐷 +
𝑄
𝐿




Where MFb and MFf represent the molar fractions of the bound and free substrate 200 
respectively. Inserting Eq. 7 in Eq. 8 gives a final expression of D as a function of L0 that can 201 
be fitted to the experimental data (keeping S0 constant, see section 2..2.2 and Table 2) and 202 
allows for the quantification the diffusivities of bound and free API (Db and Df respectively). 203 
Partitioning of API into liposomes (Plip/w) was calculated using the following equation: 204 
𝑃 / =







Where A0 represents the initial API amount in the reference experiments (i.e. no liposomes), 205 
Alip the amount in the liposomes experiments and V0  and Vlip represent the liposome-free 206 
volume fraction of the injected volume (estimated to be 22 µL) and the volume occupied by 207 
the liposomes (estimated to be 3 µL) respectively.  208 
2.3 Nuclear magnetic resonance (NMR) spectroscopy 209 
10 µL of a 7.5 mM Na-ibu non-isotonic PBS solution (10% deuterated water) were added to 210 
590 µL of a 5.7 mM HPBCD non isotonic PBS solution (10% deuterated water) in a standard 211 
5 mm NMR tube, yielding a final solution of concentrations of 0.1 mM and 5.6 mM for Na-212 
ibu and HPBCD respectively. The NMR experiments were performed employing an Agilent 213 
DD2 NMR (Agilent Technologies, Santa Clara, USA) spectrometer functioning at a proton 214 
frequency of 599.671 MHz. Temperature was stabilized at 30 ̊C during all experiments. 215 
Diffusion constants were measured using a standard DgsteSL sequence with convection 216 
compensation and treated with the DOSY package. 217 
3. Results and discussion 218 
3.1 quantification of diffusion coefficients in absence of binding agents 219 
In table 3 the results from the diffusion studies of the API (caf, hc, ibu and ket) in PBS 220 
solutions without binding agents (i.e. neither HPBCD nor liposomes) are reported. In all 221 
experiments, the data recording position (hm) was used as fixed parameter (0.51 cm) whereas 222 
A0 and D0 were fitting parameters. The nominal equilibrium concentration (ceq) correlates 223 
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very well (R2 of 0.99) with A0, indication of very good correspondence between experimental 224 
and computational data.  225 
Table 3. Nominal equilibrium concentration (ceq), initial amount (A0), width of the initial 226 
distribution (σ) and reference diffusivities (D0) of the reference drug (caf, hc, ibu and ket) 227 
samples. All parameters were obtained by fitting the analytical solution of diffusion equation 228 
(Eq. 3) to experimental data of API solutions recorded at x=0.51cm. 229 
Sample 
 
ceq A0 σ D0 
 (mM)   (10-6 cm2/sec) 
caf0 0.03 0.231 0.104 9.120 
hc0 0.02 0.145 0.111 6.442 
ibu0 0.05 0.331 0.101 7.788 
ket0 0.05 0.408 0.055 7.724 
     
The Stokes-Einstein equation relates the diffusion constant (D) to the radius of a hypothetical 230 






Where kB is Boltzmann’s constant. Assuming that all the experiments are performed at the 232 
same temperature (T) and that concentration of the API is so low that the viscosity (η) is not 233 
affected we can expect a linear correlation between molar volume (Vm, Table 1) and D0. 234 
Diffusion coefficient values are consistent with previous finding [20] and indeed, fitting D0 to 235 
the estimated molar volumes yields a straight line (R2=0.99). Hydrocortisone is the largest 236 
molecule within the investigated series (Vm of 281 cm3/mol, Table 1) and because of that it 237 
shows the lowest D0 (6.4 *10-6 cm2/sec) whereas caffeine, that is the smallest of the 238 
investigated compounds (Vm of 133 cm3/mol), expresses the highest D0 (9.2*10-6 cm2/sec). 239 
Ibuprofen and ketoprofen have very similar Vm (200 and 212 cm3/mol) in between caffeine 240 
and hydrocortisone and this is reflected in similar diffusivities (7.8 and 7.7 * 10-6 cm2/sec 241 
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respectively) comprised between the other two compounds (Table 3). The data reported in 242 
Table 3 are fundamental as they are the reference data to which experimental data collected 243 
from samples with solubilizing vehicles should be compared with. 244 
3.2 Diffusion coefficients in the presence of HPBCD 245 
Table 4. Nominal equilibrium concentration (ceq), calculated initial amount (A), width of the 246 
initial distribution (σ) and relative diffusivities (𝐷) of the investigated compounds (caf, hc, ibu 247 




Ceq A σ 𝑫 
 (mM) (mM)   (10-6 cm2/sec) 
Caffeine 
caf1 1 0.03 0.233 0.105 9.089 
caf2 5 // 0.223 0.104 8.335 
caf3 10 // 0.220 0.103 8.070 
caf4 25 // 0.221 0.104 7.924 
Hydrocortisone 
hc1 1 0.02 0.132 0.119 5.149 
hc2 2.5 // 0.134 0.110 4.092 
hc3 10 // 0.135 0.122 3.415 
hc4 25 // 0.132 0.121 3.400 
Ibuprofen 
ibu1 0.5 0.05 0.319 0.115 5.760 
ibu2 1 // 0.327 0.125 5.265 
ibu3 2.5 // 0.312 0.134 3.787 
ibu4 5 // 0.323 0.125 3.554 
ibu5 10 // 0.334 0.122 3.110 
Ketoprofen 
ket1 0.5 0.05 0.389 0.062 6.828 
ket2 2.5 // 0.372 0.096 5.468 
ket3 5 // 0.342 0.114 4.796 
ket4 10 // 0.357 0.122 4.061 
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ket5 25 // 0.326 0.125 3.213 
Data recorded at x=0.51 cm 
      
Fig. 1 reports the experimental data (blue line) and fit (red line) of ibuprofen in the presence 249 
of increasing HPBCD concentration (Fig. 1, ibu0-ibu5). The other compounds show similar 250 
behavior. The diffusion profiles change when the concentration of the binding agent is 251 
increased. Specifically, the slope of the rising section of the curves decreases whereas the 252 
curvature at the top becomes more gentle and the time where the maximum occurs (tmax) 253 
increases. The fitting of Eq. 3 to the experimental data was very good in all circumstances and 254 
in accordance with our previous work (fitting error below 1%, [20]). In Table 4 the initial 255 
amount (A) and diffusivities (𝐷) obtained from the data fitting are reported for each of the 256 
API investigated.  257 
It should be highlighted that, for all drugs, increasing the HPBCD concentration results in a 258 
decrement in diffusivities, showing that all compound bind to HPBCD. The magnitude of the 259 
variation depends on the binding constant and varies significantly between the investigated 260 
compounds. For instance, in the case of caffeine, even at the highest concentration of HPBCD 261 
(25 mM) the relative diffusion identified is only 14 % lower than D0 (Table 3 and 4). For all 262 
the other compounds, the impact of cyclodextrins on API diffusion is much more severe. At 263 
the highest concentration of HPBCD (25 mM), the decrease in diffusivities exceeds 50 % in 264 
the case of ibuprofen and hydrocortisone whereas for ketoprofen it is 47%. This data gives a 265 
picture of what is happening when cyclodextrins bind an API. As the HPBCD-API complex is 266 
larger than the API alone, we expect the complex to diffuse slower than the free API, as 267 
indeed is the case. In other words, binding with cyclodextrins has a negative effect on the net 268 
drug transport through the UWL. This results are in agreement with previous findings [15-17]. 269 
The data obtained in this work give also a better and clearer picture of the reason why drug 270 
transport of drugs through UWL is affected by the presence of solubilizing vehicles such as 271 
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cyclodextrins. From the data obtained in this work it is evident that for hydrocortisone, but 272 
also for the ionizable compound ibu, the gradient of concentration is produced by both free 273 
and complexed API molecules. This is demonstrated by the fact that the estimated initial drug 274 
amount of API (A) does not change significantly with increased concentration of HPBCD 275 
(Table 4, and therefore with increased API-HPBCD complexation) in the UWL. Moreover, 276 
these findings are in partial agreement with Stewart at al. [19] where they found that the net 277 
flux of itraconazole through a biomimetic barrier was proportional to the total apparent 278 
solubility of the drug in the donor (i.e. both bound and unbound API fraction in solution). 279 
However, in the present work, the total flux of all APIs investigated resulted reduced through 280 
the UWL and not improved by the presence of a solubilizer. This is already an interesting 281 
findings that exclude the role of concentration gradient as the responsible for the reduction of 282 
API flux observed. In the case of ketoprofen, there is a clear trend in reduction in A with 283 
increased HPBCD concentration (Table 4) and this could indicate that there is a decrease in 284 
ket molecules available with increased HPBCD. This could be explained by the formation of 285 
macromolecular aggregates [27] that reduces the initial concentration gradient (driving force 286 
of passive diffusion). From these data it is clear that, especially with compounds forming 287 
stable complex with HPBCD, the complex API-HPBCD is maintained also in diluted 288 
conditions (i.e. after injection), and this fact produces the reduction of API diffusing through 289 
the UWL measured. It is evident from these data that, and agreement with previous findings 290 
[15-17], cyclodextrins clearly hamper the diffusion of API through the UWL. In partial 291 
disagreement with previous reports [15] however, it appears that also hydrophilic compounds 292 
(in this case caffeine), are affected in their diffusion through the UWL at high concentration 293 
of HPBCD, even though the binding constant of caffeine to HPBCD is low [28].  294 
3.3 calculation of K, Df and Db 295 
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The decrease of the relative diffusion coefficient measured when the API are complexed with 296 
cyclodextrin depends on the binding constant. After injection at the bottom of the cuvette, free 297 
API molecules, free HPBCD and API-HPBCD complex will start to diffuse. In accordance 298 
with Stokes-Einstein equation (Eq. 10), assuming similar experimental conditions (absolute 299 
temperature (T) and viscosity of the media (η)) in each experiment, the free API and API-300 
HPBCD complexes will show different diffusivities (Df and Db respectively) determined by 301 
their size (hydrodynamic radius (r)). 302 
In Fig. 2 the relationship between apparent diffusivity (𝐷) and HPBCD concentration is 303 
reported for all the compound investigated. Fitting the experimental data with equation 8 and 304 
9 (red line, Fig. 2) it is possible to obtain numerical values for the equilibrium constant (K) 305 
and the diffusivities of bound and free API (Db and Df respectively). The results are reported 306 
in Table 5.  307 
Table 5. Equilibrium constant (K), diffusivity of free API (Df) and complexed API (Db) 308 
identified for each of the investigated compound (caf, hc, ibu, ket) in the experiment 309 
performed in the presence of HPBCD. 310 
API K Df Db 
 M-1 10-6 cm2/sec 10-6 cm2/sec 
caf 243 ± 151 9.2 ± 0.1 7.6 ± 0.3 
hc 1028 ± 246 6.5 ± 0.1  3.2 ± 0.1 
ibu 4058 ± 2890 7.6 ± 0.3  3.1 ± 0.3 
ket 381 ± 102 7.5 ± 0.2 2.9 ± 0.3 
 311 
For all compounds, Df is very similar to D0 (Table 3, discrepancy of 1%). Moreover, the 312 
equilibrium constants obtained are in good agreement with literature data [15, 28-31]. Ibu and 313 
hc are the compounds with the strongest equilibrium constant and therefore their diffusion 314 
through the UWL is most affected. For ibu, ket and hc, Db is close to 3*10-6cm2/sec. This 315 
value seems very reasonable, as the size of the inclusion complex API-HPBCD is mostly due 316 
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to the cyclodextrin (Mw of 1.4 kDa) and DOSY NMR results showed that the diffusion 317 
constant for HPBCD in water is 2.9*10-6 cm2/s. Moreover, NMR results with Na-ibu 318 
evidenced that API-HPBCD complex diffuses at the same rate as HPBCD alone. Caffeine 319 
expresses a much higher value for Db (over 7*10-6 cm2/sec). Theoretically, this value should 320 
be much lower and close to 3*10-6 cm2/sec (as with the other API investigated). It is quite 321 
plausible that the Caf-HPBCD complex is more affected than the others by rapid on-and-off 322 
kinetics (due to poor complex stability, see equilibrium constant values in table 5). This fact 323 
makes a correct estimation of Db impossible with the current technique, and this might be an 324 
issue for all complexes with low K. We are aware that the obtained value lies outside the 325 
expected range and will investigate the system further in the near future. From these data we 326 
can anyway conclude that measured reduction in API flux through the UWL in the presence 327 
of HPBCD is not due to a reduction in the concentration gradient but it is mostly due to the 328 
reduction in relative diffusivity of API. In fact, API-HPBCD complexes diffuse much slower 329 
through the UWL then free APIs (Db<<Df, see Table 5), therefore 𝐷 will decrease with 330 
increasing concentration of HPBCD. This reduction in apparent diffusivity is, in practice, 331 
directly corresponding to a reduction in the amount of API passing through the UWL. It 332 
appears also clear from our results that the more stable the complex API-HPBCD is (i.e. 333 
higher is K), the more significant this phenomenon will be.  334 
3.4 Partitioning and relative diffusivities 335 
The experiments involving liposomes were conducted similarly to the cyclodextrins ones but 336 
in this case each of the API was incubated for 10 minutes previous injection in the cuvette 337 
with a liposomal dispersion containing 25 mM phosphatidylcholine S-100 of 400 nm average 338 
diameter. In this case, liposomes due to their sizes (dm. = 400 nm) were located on the bottom 339 
of the cuvette for the duration of the experiment, differently from the cyclodextrin 340 
experiments where the API-HPBCD complexes were also diffusing. For all compounds 341 
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investigated, a reduction in apparent mass transport of API through the UWL was measurable 342 
when liposomes were present. The fitting to the experimental data in this case reveals that, 343 
differently from cyclodextrins, the initial amount of API measured (A) was reduced after 10 344 
min incubation with liposomes for ketoprofen, ibuprofen and hydrocortisone but not for 345 
caffeine. Since the experimental set up used was a closed system (i.e. mass preservation) it 346 
can be assumed that all the material that did not diffuse through the cuvette was sequestered 347 
by the phospholipid bilayers. Interestingly, liposomes did not only incorporate significant 348 
amount of API molecules, but they also affect the apparent diffusivity ((𝐷) of each of the 349 
compounds investigated (i.e. liposomes strongly retain API). This indicated that, as drug 350 
diffusion occurs, the drug is release again, but with a kinetics proportional to the affinity of 351 
the API for the phospholipid bilayers (indicatively expressed by the LogD7.4, Table 1).  In Fig. 352 
3, the liposome/water partition coefficient (Plip/w, gray column) calculated accordingly to Eq.  353 
9 as well as the apparent diffusivities measured (blue dots) are reported for each of the drugs. 354 
As it can be seen, hc is the most incorporated compound into the phospholipid bilayer (Fig. 355 
3), with an almost 4 times higher distribution of API molecules in the lipophilic bilayer in 356 
comparison to the water phase. Ibu and ket show very comparable behaviors, as expected 357 
from the molecular physicochemical properties (comparable pKa (Table 1) and chemical 358 
structure). For both drugs, molecules distribute approximately two times more in the lipid 359 
phase than in the water phase. Caffeine is quite hydrophilic (negative logD7.4, Table 1) and 360 
therefore its very low partition into lipophilic environment is not surprising. The experimental 361 
approach utilized in this work gives additive information on the relative diffusivities of the 362 
API in the presence of liposomes. From the results reported in Fig. 3, it is evident that also 363 
relative diffusivities of API are reduced by the presence of liposomes, also for hydrophilic 364 
compound. For example, caf relative diffusivity is reduced by approx. 20% in comparison to 365 
D0 (Table 2) whereas hc diffusivity is reduced down to 55% of its reference diffusion (Table 366 
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2). These data allow to make some interesting considerations. First, interaction of API 367 
molecules with phospholipid bilayers are extremely fast as equilibrium is reached within 10 368 
min. Second, in the case of phospholipid vesicles, it is clear that the reduction in apparent flux 369 
of API through UWL is affected by the reduction in concentration gradient induced (dc/dx) by 370 
the segregation of drug molecules into liposomes. Unfortunately, in the case of liposomes it 371 
was not possible to estimate a real equilibrium constant API-liposome as in the case of 372 
HPBCD, since the stoichiometry of reaction API-liposomes was unknown. However, using as 373 
parameter the variation within relative diffusivity (𝐷) and reference diffusivity (D0) it is 374 
possible to estimate that the binding between hc and the phospholipid bilayers should be 375 
approx. two-times stronger than ibuprofen and ketoprofen and almost three-times stronger 376 
than with caffeine.   377 
4. Conclusion 378 
In this work the interaction of four APIs with classical solubilizing vehicles (cyclodextrins 379 
and liposomes) has been successfully studied in unstirred aqueous conditions. The transport 380 
through the UWL of drug molecules is significantly affected by the presence of both 381 
cyclodextrins and liposomes. The extent is connected to the intrinsic physicochemical 382 
properties of API molecules. Specifically, the diffusivity of small hydrophilic compounds 383 
such as caffeine is not strongly hampered by the presence of solubilizing vehicles whereas, for 384 
compounds with higher lipophilicity (ibuprofen, ketoprofen and hydrocortisone), the 385 
reduction in transport rate results quite remarkable. In both cases (HPBCD and liposomes) the 386 
diffusion of drug through UWL is limited by drug sequestration and consequent reduced mass 387 
flux. In the case of cyclodextrins, empirical data are the results of the diffusion of both free 388 
drug and drug-HPBCD complex whereas, in the case of liposomes, the experimental data 389 
reassemble the diffusion of the free drug only, as we can assume that the liposomes are 390 
stationary (on the relevant time scales). This is due to the much slower diffusivity of 391 
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liposomes in respect to drug molecules. In both cases however, the mathematical approach 392 
used results efficient in order to obtain reliable information on passive drug diffusion through 393 
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Figure 1. Diffusion profiles of ibuprofen through the unstirred water layer in absence (ibu0) 474 
and in the presence (ibu1 to ibu5) of increasing concentration (from 1 mM to 10 mM) of 475 
hydroxypropyl-β-cyclodextrin. The blue lines represent the experimental data recorded at 0.51 476 
cm from origin of diffusion whereas the red lines represent the data fitting.  477 




Figure 2. Relationship between relative diffusion coefficient (𝐷) and hydroxypropyl-β-480 
cyclodextrin (HPBCD) concentration for all the investigated compounds. The red line 481 
represents the data fitting of Eq. 7-8 to experimental values. 482 




Figure 3. Partition coefficient liposomes/water (Plip/w) and relative diffusion coefficients (𝐷) 485 
measured for all investigated compounds in the experiments performed in the presence of 486 
phospholipid vesicles (25 mM phosphatidylcholine S-100 concertation, liposomes diameter of  487 
400 nm).  488 
 489 
 490 
